Antios reportedly shut down; Clene's long-term ALS data; Keytruda, Lenvima's lung cancer failures
25 Sep 2023
Phase 2Clinical Trial Failure
Hepatitis B startup Antios Therapeutics shuts down — report
An FDA hold tanked Antios Therapeutics, a hepatitis B biotech that had raised about $200 million before shutting down earlier this year, per Fierce Biotech. The FDA had placed a hold on Antios’ Phase IIa trial in May 2022 after a patient in a triple combination portion of the study had hypotension and bradycardia. Assembly Biosciences quickly axed its clinical trial collaboration agreement with Antios. — Kyle LaHucik
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.